drugset / Trial / NCT06333769
Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
To explore the complete response (CR) rate of modified short-course radiotherapy combined with CAPOX and tislelizumab for locally Advanced Mid-low Rectal Cancer
Timeline
- Start
- 2024-07-12
- Primary completion
- 2025-08-10
- Completion
- 2025-08-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | — |